<DOC>
	<DOCNO>NCT00139919</DOCNO>
	<brief_summary>This study assess tolerability bifeprunox progressive elimination titration step achieve short tolerated titration dose dose 40 mg/day either schizophrenia bipolar disorder subject . Study duration 2 month optional open-label 26-week extension study .</brief_summary>
	<brief_title>Progressively Decreasing Titration Schedules Bifeprunox Subjects With Schizophrenia Bipolar Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<criteria>Subjects current Diagnosis Schizophrenia , Bipolar Type I Disorder accord DSMIV TR criterion Age 18 55 Body weight 100250 lb Be sufficiently stable allow discontinuation antipsychotic medication Acutely psychotic subject Subjects acutely manic Subjects psych diagnosis Bipolar Type I Disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>Decreasing Titration Study</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>Bipolar</keyword>
	<keyword>Pharmacokinetic</keyword>
</DOC>